Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Findcure Bio Raises $14.5 Million Series B to Advance Radiopharmaceutical Platform

Fineline Cube Feb 14, 2026
Company Deals

Siemens Healthineers Deepens Mayo Clinic Partnership on AI Neurology and Precision Oncology

Fineline Cube Feb 14, 2026
Company Deals

VivaVision Biotech Files Hong Kong IPO to Advance Ophthalmology Pipeline

Fineline Cube Feb 14, 2026
Company Deals

Genhouse Bio Partners with Gilead on $1.5 Billion Synthetic Lethal Cancer Project GH31

Fineline Cube Feb 14, 2026
Company Deals

First Imaging Raises $14.5 Million to Advance AI-Powered Intraoperative Imaging

Fineline Cube Feb 13, 2026
Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026
Company Drug

Sino Biopharma’s Benmelstobart Secures Fourth NMPA Approval for Stage III NSCLC – Expanding PD‑L1 Franchise in China

Fineline Cube Feb 14, 2026
Company Drug

Mabworks’ Obexelimab β Wins NMPA Approval as First Domestic NMOSD Therapy

Fineline Cube Feb 14, 2026
Company

Sanyou Biopharmaceuticals Expands Global Reach with New Cambridge Office

Fineline Cube Mar 6, 2023

Sanyou Biopharmaceuticals, a leading provider of biotech CRDMO services, is set to open a new...

Company Drug

Sanofi’s Dupixent Receives Priority Review for Prurigo Nodosa Treatment

Fineline Cube Mar 6, 2023

French pharmaceutical major Sanofi (NASDAQ: SNY) has announced that it has received priority review status...

Policy / Regulatory

China’s Premier Li Keqiang Highlights Economic and Social Advances in Annual Report

Fineline Cube Mar 6, 2023

Premier Li Keqiang delivered his annual Government Work Report at the “Two Sessions” meeting, which...

Company Drug

Eli Lilly’s Retevmo Launched in China by Innovent Biologics

Fineline Cube Mar 6, 2023

Eli Lilly & Co’s (NYSE: LLY) Retevmo (selpercatinib) has been officially launched in the Chinese...

Company Deals

QL Biopharm Raises Series B Funding for Protein Drug Development

Fineline Cube Mar 6, 2023

QL Biopharm, a Beijing-based developer of Escherichia coli-based protein drugs, has reportedly raised RMB 100...

Company Drug

Huahai Pharma’s HB0025 Receives NMPA Approval for Clinical Trials

Fineline Cube Mar 6, 2023

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received clinical...

Company Drug

Hengrui’s Adebrelimab Receives NMPA Approval for Lung Cancer Treatment

Fineline Cube Mar 6, 2023

Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced that it has received marketing approval from the...

Company Deals

Siyi Intelligence Raises Series A Funding for Neural Rehabilitation Solutions

Fineline Cube Mar 6, 2023

Siyi Intelligence, a developer of soft rehabilitation robots based in Shanghai, has reportedly raised close...

Company Drug

Sino Biopharmaceutical’s Bevacizumab Biosimilar Approved by NMPA

Fineline Cube Mar 6, 2023

Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received marketing approval from the...

Company Drug

Mabwell’s 9MW3911 Monoclonal Antibody Accepted for NMPA Review

Fineline Cube Mar 6, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that a clinical trial filing...

Company Drug

Venus Medtech Completes Patient Enrollment for Liwen RF Ablation System Study

Fineline Cube Mar 6, 2023

China-based Venus Medtech (Hangzhou) Inc. (HKG: 2500) has announced that all patients have been successfully...

Company Deals

PulseCare Raises Pre-Series A Funding for Minimally Invasive Treatment Devices

Fineline Cube Mar 6, 2023

PulseCare, a Shenzhen-based maker of minimally and non-invasive treatment devices, has reportedly raised “tens of...

Company Deals R&D

HKUST and PhIRDA Sign MoU to Establish Innovation Centers

Fineline Cube Mar 4, 2023

The Hong Kong University of Science and Technology (HKUST) and the China Pharmaceutical Innovation and...

Policy / Regulatory

China Releases Blue Book on Medical Insurance Fund Supervision

Fineline Cube Mar 3, 2023

The China Health Insurance and Social Sciences Academic Press has jointly released the “Blue Book...

Policy / Regulatory

NHC Recommends Simcere and Junshi COVID-19 Therapies in Updated Guidelines

Fineline Cube Mar 3, 2023

The National Health Commission (NHC) has released a notification including Simcere Pharmaceutical Group’s (HKG: 2096)...

Company Deals

ClinChoice Acquires Cromsource to Expand Global CRO Footprint

Fineline Cube Mar 3, 2023

Sino-US Contract Research Organization (CRO) ClinChoice Medical Development has announced the acquisition of Cromsource S.r.l.,...

Company Drug

Atom Bioscience’s ABP-671 Shows Positive Phase IIa Results in Gout Treatment

Fineline Cube Mar 3, 2023

China-based Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd) has announced positive results from...

Company Deals

Echo Biotech Secures Series A++ Funding for Exosomes Drug Development

Fineline Cube Mar 3, 2023

Echo Biotech, a Beijing-based exosomes drug developer, has reportedly raised “tens of millions” of renminbi...

Company Medical Device

AffaMed Technologies Completes First Patient Implantation for MINI WELL IOL

Fineline Cube Mar 3, 2023

AffaMed Technologies, a joint venture between AffaMed Therapeutics and SIFI S.p.A., has announced the completion...

Company Drug

CSPC Pharmaceutical Initiates Phase III Study for Mitoxantrone Liposome in Nasopharyngeal Carcinoma

Fineline Cube Mar 3, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced the first patient dosing in a...

Posts pagination

1 … 514 515 516 … 625

Recent updates

  • Sino Biopharma’s Benmelstobart Secures Fourth NMPA Approval for Stage III NSCLC – Expanding PD‑L1 Franchise in China
  • Mabworks’ Obexelimab β Wins NMPA Approval as First Domestic NMOSD Therapy
  • Findcure Bio Raises $14.5 Million Series B to Advance Radiopharmaceutical Platform
  • Siemens Healthineers Deepens Mayo Clinic Partnership on AI Neurology and Precision Oncology
  • VivaVision Biotech Files Hong Kong IPO to Advance Ophthalmology Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sino Biopharma’s Benmelstobart Secures Fourth NMPA Approval for Stage III NSCLC – Expanding PD‑L1 Franchise in China

Company Drug

Mabworks’ Obexelimab β Wins NMPA Approval as First Domestic NMOSD Therapy

Company Deals

Findcure Bio Raises $14.5 Million Series B to Advance Radiopharmaceutical Platform

Company Deals

Siemens Healthineers Deepens Mayo Clinic Partnership on AI Neurology and Precision Oncology

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.